Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc.; Monday September 21, 1998
Glaxo Wellcome said in a statement the drug will be available to patients failing current regimens with protease inhibitors. Patients must be enrolled in the early access program by their physicians beginning Monday.
"By taking this unique approach to an early access program, we hope to capture some clinical information regarding Agenerase that might help guide future antiretroviral treatment decisions," said Dr. Lynn Smiley, a Glaxo Wellcome vice president.
Agenerase was discovered by scientists at Vertex Pharmaceuticals Inc. (Nasdaq:VRTX - news) of Cambridge, Massachusetts. Glaxo Wellcome said it has been responsible for product formulation, manufacture of the drug, design and implementation of all clinical trials, and submissions to the U.S. Food and Drug Administration.
980921
RE980913
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .